Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJun 02, 2025
DataAggregated Company Financials
Companies21
  • 7D2.3%
  • 3M-26.5%
  • 1Y-47.1%
  • YTD-26.6%

The Healthcare industry is up 2.3% in the last week, with Novo Nordisk up 2.4%. In the past year, the industry is down 47%. Looking forward, earnings are forecast to grow by 12% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 02 Jun 2025DKK 2.5tDKK 423.9bDKK 124.7b30.4x19.9x5.8x
Wed, 30 Apr 2025DKK 2.4tDKK 409.2bDKK 121.3b22x19.4x5.7x
Fri, 28 Mar 2025DKK 2.6tDKK 409.5bDKK 121.3b22.9x21.6x6.4x
Sun, 23 Feb 2025DKK 3.3tDKK 410.0bDKK 121.4b28.1x27.6x8.2x
Tue, 21 Jan 2025DKK 3.0tDKK 387.4bDKK 111.3b28.4x27x7.7x
Thu, 19 Dec 2024DKK 4.0tDKK 387.4bDKK 111.3b30.8x35.6x10.2x
Sat, 16 Nov 2024DKK 3.7tDKK 387.3bDKK 110.9b31.6x33.5x9.6x
Mon, 14 Oct 2024DKK 4.2tDKK 372.0bDKK 107.1b37x39.3x11.3x
Wed, 11 Sep 2024DKK 4.5tDKK 372.0bDKK 107.2b35x41.9x12.1x
Fri, 09 Aug 2024DKK 4.4tDKK 369.1bDKK 106.9b36.2x41.4x12x
Sun, 07 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.3x46.2x13.8x
Tue, 04 Jun 2024DKK 4.7tDKK 355.2bDKK 106.2b36.1x43.9x13.1x
Thu, 02 May 2024DKK 4.6tDKK 341.4bDKK 99.6b33.9x45.8x13.4x
Sat, 30 Mar 2024DKK 4.5tDKK 341.2bDKK 99.6b39.2x45.4x13.3x
Mon, 26 Feb 2024DKK 4.4tDKK 340.1bDKK 98.9b38.2x44.2x12.9x
Wed, 24 Jan 2024DKK 3.7tDKK 320.5bDKK 90.0b35x41.5x11.6x
Fri, 22 Dec 2023DKK 3.6tDKK 320.5bDKK 90.0b33.2x40.4x11.3x
Sun, 19 Nov 2023DKK 3.6tDKK 320.5bDKK 90.0b33.7x40x11.2x
Tue, 17 Oct 2023DKK 3.7tDKK 305.5bDKK 82.2b29.9x44.5x12x
Thu, 14 Sep 2023DKK 3.5tDKK 305.5bDKK 82.2b35.1x43x11.6x
Sat, 12 Aug 2023DKK 3.3tDKK 301.3bDKK 81.0b41.3x40.8x11x
Mon, 10 Jul 2023DKK 2.9tDKK 287.0bDKK 75.5b39.4x38.9x10.2x
Wed, 07 Jun 2023DKK 3.1tDKK 287.2bDKK 75.5b41.3x40.9x10.8x
Fri, 05 May 2023DKK 3.0tDKK 272.7bDKK 68.9b41.3x44.1x11.2x
Sun, 02 Apr 2023DKK 3.0tDKK 291.1bDKK 69.0b38.5x43.6x10.3x
Tue, 28 Feb 2023DKK 2.8tDKK 292.0bDKK 68.8b37.9x41.2x9.7x
Thu, 26 Jan 2023DKK 2.7tDKK 275.9bDKK 66.3b37x40.4x9.7x
Sat, 24 Dec 2022DKK 2.7tDKK 276.1bDKK 66.3b36.7x40.2x9.6x
Mon, 21 Nov 2022DKK 2.4tDKK 276.2bDKK 66.3b36.2x36.5x8.8x
Wed, 19 Oct 2022DKK 2.4tDKK 261.3bDKK 62.4b36.1x38.1x9.1x
Fri, 16 Sep 2022DKK 2.3tDKK 261.1bDKK 62.4b34.4x36.9x8.8x
Sun, 14 Aug 2022DKK 2.3tDKK 257.3bDKK 62.6b34.5x37.3x9.1x
Tue, 12 Jul 2022DKK 2.4tDKK 247.9bDKK 59.9b36.9x40.2x9.7x
Thu, 09 Jun 2022DKK 2.4tDKK 247.5bDKK 59.7b36.3x39.7x9.6x
Price to Earnings Ratio

39.7x


Total Market Cap: DKK 2.4tTotal Earnings: DKK 59.7bTotal Revenue: DKK 247.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 38.4x202320242025
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 19.9x which is lower than its 3-year average PE of 38.5x.
  • The 3-year average PS ratio of 10.4x is higher than the industry's current PS ratio of 5.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 28% per year over the last three years.
  • Revenues for these companies have grown 20% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market1.12%
Healthcare2.25%
Biotech3.75%
Life Sciences2.77%
Pharma2.34%
Medical Equipment0.73%
Healthcare Services-1.40%
Healthtech-3.68%
Industry PE
  • Investors are most optimistic about the Life Sciences industry which is trading above its 3-year average PE ratio of 101x.
    • Analysts are expecting annual earnings growth of 13.6%, which is lower than the prior year's growth of 17.6% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 60% over the next 5 years.
  • This is better than its past earnings decline of 83% per year.
  • In contrast, the Biotech industry is expected to see its earnings grow by 5.5% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ALK B ALK-AbellóDKK 177.901.3%
+DKK 486.6m		16.4%PE42x
GMAB GenmabDKK 1.38k0.4%
+DKK 369.5m		-29.4%PE11.4x
ZEAL Zealand PharmaDKK 453.500.8%
+DKK 261.6m		-30.6%PS575.6x
BAVA Bavarian NordicDKK 173.001.2%
+DKK 155.7m		-7.1%PE10.2x
CHEMM ChemoMetecDKK 528.001.4%
+DKK 130.5m		54.7%PE54.3x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlans & PricingLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & EnterpriseWhat's New
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

DEMANT

DKK 257.00

Demant

7D

-2.0%

1Y

-20.6%

Demant (CPH:DEMANT) Has More To Do To Multiply In Value Going Forward

Jun 02
Demant (CPH:DEMANT) Has More To Do To Multiply In Value Going Forward

ZEAL

DKK 453.50

Zealand Pharma

7D

0.8%

1Y

-30.6%

PEG

DKK 0.097

Pharma Equity Group

7D

15.2%

1Y

-63.9%

EMBLA

DKK 32.70

Embla Medical hf

7D

-3.8%

1Y

17.2%

HLUN B

DKK 36.34

H. Lundbeck

7D

-2.2%

1Y

-1.9%

H. Lundbeck A/S (CPH:HLUN B) Surges 25% Yet Its Low P/E Is No Reason For Excitement

May 28
H. Lundbeck A/S (CPH:HLUN B) Surges 25% Yet Its Low P/E Is No Reason For Excitement

COLO B

DKK 635.60

Coloplast

7D

-0.4%

1Y

-21.2%

Investors Still Waiting For A Pull Back In Coloplast A/S (CPH:COLO B)

May 25
Investors Still Waiting For A Pull Back In Coloplast A/S (CPH:COLO B)

AMBU B

DKK 101.30

Ambu

7D

0.2%

1Y

-22.0%

GUBRA

DKK 389.60

Gubra

7D

-3.5%

1Y

18.8%

author-image

AbbVie Agreement And Clinical Trials Will Unlock New Avenues

Strategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra.

NOVO B

DKK 453.65

Novo Nordisk

7D

-1.4%

1Y

-50.9%

NNIT

DKK 68.40

NNIT

7D

-2.3%

1Y

-37.4%

These 4 Measures Indicate That NNIT (CPH:NNIT) Is Using Debt Reasonably Well

May 16
These 4 Measures Indicate That NNIT (CPH:NNIT) Is Using Debt Reasonably Well

GMAB

DKK 1,379.50

Genmab

7D

0.4%

1Y

-29.4%

BAVA

DKK 173.00

Bavarian Nordic

7D

1.2%

1Y

-7.1%

BIOPOR

DKK 1.41

BioPorto

7D

0.9%

1Y

-16.9%

ALK B

DKK 177.90

ALK-Abelló

7D

1.3%

1Y

16.4%

CHEMM

DKK 528.00

ChemoMetec

7D

1.4%

1Y

54.7%

Getting In Cheap On ChemoMetec A/S (CPH:CHEMM) Is Unlikely

Apr 06
Getting In Cheap On ChemoMetec A/S (CPH:CHEMM) Is Unlikely

STRAP

DKK 992.00

Strategic Partners

7D

-8.1%

1Y

-0.8%